143 related articles for article (PubMed ID: 30297515)
1. Relationship between Circulating Inflammation Proteins and Lung Cancer Diagnosis in the National Lung Screening Trial.
Brown D; Zingone A; Yu Y; Zhu B; Candia J; Cao L; Ryan BM
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):110-118. PubMed ID: 30297515
[TBL] [Abstract][Full Text] [Related]
2. Circulating inflammation markers and prospective risk for lung cancer.
Shiels MS; Pfeiffer RM; Hildesheim A; Engels EA; Kemp TJ; Park JH; Katki HA; Koshiol J; Shelton G; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2013 Dec; 105(24):1871-80. PubMed ID: 24249745
[TBL] [Abstract][Full Text] [Related]
3. Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
Shiels MS; Katki HA; Hildesheim A; Pfeiffer RM; Engels EA; Williams M; Kemp TJ; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26220734
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.
Pine SR; Mechanic LE; Enewold L; Chaturvedi AK; Katki HA; Zheng YL; Bowman ED; Engels EA; Caporaso NE; Harris CC
J Natl Cancer Inst; 2011 Jul; 103(14):1112-22. PubMed ID: 21685357
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein and risk of lung cancer.
Chaturvedi AK; Caporaso NE; Katki HA; Wong HL; Chatterjee N; Pine SR; Chanock SJ; Goedert JJ; Engels EA
J Clin Oncol; 2010 Jun; 28(16):2719-26. PubMed ID: 20421535
[TBL] [Abstract][Full Text] [Related]
6. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B; Eldridge RC; Pfeiffer RM; Shiels MS; Kemp TJ; Guillemette C; Hartge P; Sherman ME; Brinton LA; Black A; Chaturvedi AK; Hildesheim A; Berndt SI; Safaeian M; Pinto L; Wentzensen N
Int J Cancer; 2017 Feb; 140(3):600-610. PubMed ID: 27770434
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.
Bittoni MA; Focht BC; Clinton SK; Buckworth J; Harris RE
Int J Oncol; 2015 Oct; 47(4):1537-44. PubMed ID: 26323323
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Cytokines and Lung Cancer Risk in 3 Prospective Studies.
Brenner DR; Fanidi A; Grankvist K; Muller DC; Brennan P; Manjer J; Byrnes G; Hodge A; Severi G; Giles GG; Johansson M; Johansson M
Am J Epidemiol; 2017 Jan; 185(2):86-95. PubMed ID: 27998891
[TBL] [Abstract][Full Text] [Related]
10. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer.
Kubasiak JC; Seder CW; Pithadia R; Basu S; Fhied C; Phillips WW; Daly S; Shersher DD; Yoder MA; Chmielewski G; Edell ES; Maldonado F; Liptay MJ; Borgia JA
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):727-34.e1-3; discussion 734. PubMed ID: 25312225
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies.
Zeng F; Wei H; Yeoh E; Zhang Z; Ren ZF; Colditz GA; Tworoger SS; Su X
Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1231-9. PubMed ID: 27277846
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial.
Balekian AA; Tanner NT; Fisher JM; Silvestri GA; Gould MK
Ann Am Thorac Soc; 2016 Sep; 13(9):1568-74. PubMed ID: 27387658
[TBL] [Abstract][Full Text] [Related]
13. Serum C-reactive protein and risk of lung cancer: a case-control study.
Xu M; Zhu M; Du Y; Yan B; Wang Q; Wang C; Zhao J
Med Oncol; 2013 Mar; 30(1):319. PubMed ID: 23254959
[TBL] [Abstract][Full Text] [Related]
14. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program.
Robbins HA; Alcala K; Moez EK; Guida F; Thomas S; Zahed H; Warkentin MT; Smith-Byrne K; Brhane Y; Muller D; Feng X; Albanes D; Aldrich MC; Arslan AA; Bassett J; Berg CD; Cai Q; Chen C; Davies MPA; Diergaarde B; Field JK; Freedman ND; Huang WY; Johansson M; Jones M; Koh WP; Lam S; Lan Q; Langhammer A; Liao LM; Liu G; Malekzadeh R; Milne RL; Montuenga LM; Rohan T; Sesso HD; Severi G; Sheikh M; Sinha R; Shu XO; Stevens VL; Tammemägi MC; Tinker LF; Visvanathan K; Wang Y; Wang R; Weinstein SJ; White E; Wilson D; Yuan JM; Zhang X; Zheng W; Amos CI; Brennan P; Johansson M; Hung RJ
Ann Epidemiol; 2023 Jan; 77():1-12. PubMed ID: 36404465
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
16. Circulating Inflammation Proteins Associated With Lung Cancer in African Americans.
Meaney CL; Mitchell KA; Zingone A; Brown D; Bowman E; Yu Y; Wenzlaff AS; Neslund-Dudas C; Pine SR; Cao L; Schwartz AG; Ryan BM
J Thorac Oncol; 2019 Jul; 14(7):1192-1203. PubMed ID: 30953795
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
[TBL] [Abstract][Full Text] [Related]
19. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
[TBL] [Abstract][Full Text] [Related]
20. Vasculature surrounding a nodule: A novel lung cancer biomarker.
Wang X; Leader JK; Wang R; Wilson D; Herman J; Yuan JM; Pu J
Lung Cancer; 2017 Dec; 114():38-43. PubMed ID: 29173763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
